Relevant bibliographies by topics / Symbioflor 2

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Symbioflor 2'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Symbioflor 2.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Symbioflor 2"

1

Kocijancic, Dino, Sebastian Felgner, Michael Frahm, et al. "Therapy of solid tumors using probiotic Symbioflor-2 - restraints and potential." Oncotarget 7, no. 16 (2016): 22605–22. http://dx.doi.org/10.18632/oncotarget.8027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schlee, Miriam, Kurt Zimmermann, Hermann Huber, Klaus Fellermann, Eduard Stange та Jan Wehkamp. "M1200 Probiotic E. coli (Symbioflor®2) Treatment Mediates Antimicrobial β-Defensin (HBD-2) Synthesis and Fecal Excretion in Humans". Gastroenterology 134, № 4 (2008): A—359. http://dx.doi.org/10.1016/s0016-5085(08)61675-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schlee, M., K. Zimmermann, H. Huber, K. Fellermann, E. Stange та J. Wehkamp. "4 PROBIOTIC E. COLI (SYMBIOFLOR® 2) TREATMENT MEDIATES ANTIMICROBIAL β-DEFENSIN (HBD-2) SYNTHESIS AND FECAL EXCRETION IN HUMANS". Journal of Crohn's and Colitis Supplements 2, № 1 (2008): 2. http://dx.doi.org/10.1016/s1873-9954(08)70005-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kitz, Richard, Ute Martens, Egmont Zieseniß, Paul Enck, and Markus Rose. "Probiotic E.faecalis — adjuvant therapy in children with recurrent rhinosinusitis." Open Medicine 7, no. 3 (2012): 362–65. http://dx.doi.org/10.2478/s11536-011-0160-8.

Full text
Abstract:
AbstractSinusitis is a frequent complication of respiratory tract infections. Probiotics are perceived to be useful in infections, allergies, and inflammations. Our prospective trial stratified 204 children with recurrent rhinosinusitis by age (2–11 years, 54m:64f; 12–18 years, 39m:47f) and assigned them to standard treatment (antibiotics, anticongestants) or additional 60 days Symbioflor-1 (SF1; Enterococcus faecalis 1.5–4.5x107 CFU). The number of sinusitis episodes was lower in SF1-treated patients (2.52±0.91) than among controls (3.27±1.36; p=0.01). Mean duration of the first sinusitis epi
APA, Harvard, Vancouver, ISO, and other styles
5

Wassenaar, T. M., C. Beimfohr, T. Geske, and K. Zimmermann. "Voluntarily exposure to a single, high dose of probiotic Escherichia coli results in prolonged colonisation." Beneficial Microbes 5, no. 4 (2014): 367–75. http://dx.doi.org/10.3920/bm2013.0087.

Full text
Abstract:
The ability of probiotic Escherichia coli to colonise the human gut was determined in a volunteer study following national (German) regulations. Five persons voluntarily took a single, high dose of Symbioflor®2, which contains 6 different probiotic E. coli genotypes, to assess tolerance of the product, after which presence of E. coli in their faeces was tested for a follow-up period of 30 weeks. Intake of the product did not result in severe side effect in any of the individuals, though mild side effects were observed. Stool analysis showed that the probiotic E. coli had colonised all five per
APA, Harvard, Vancouver, ISO, and other styles
6

Zschüttig, Anke, Christian Auerbach, Simone Meltke, et al. "Complete Sequence of Probiotic Symbioflor 2 Escherichia coli Strain G3/10 and Draft Sequences of Symbioflor 2 E. coli Strains G1/2, G4/9, G5, G6/7, and G8: TABLE 1." Genome Announcements 3, no. 2 (2015). http://dx.doi.org/10.1128/genomea.01330-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schlee, M., K. Fellermann, K. Zimmermann, H. Huber, EF Stange та J. Wehkamp. "Probiotic E. coli (Symbioflor®2) treatment mediates antimicrobial β-defensin (hBD-2) synthesis and fecal excretion in humans". Zeitschrift für Gastroenterologie 46, № 09 (2008). http://dx.doi.org/10.1055/s-0028-1089566.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Symbioflor 2"

1

Zschüttig, Anke. "Escherichia coli als probiotischer Wirkstoff von Arzneimitteln - Molekulare und funktionelle Charakterisierung gesundheitsfördernder Stämme." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2012. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-92646.

Full text
Abstract:
Aus E. coli bestehende probiotische Produkte wie Mutaflor (Ardeypharm, Herdecke) und Symbioflor 2 (SymbioPharm, Herborn) werden seit Jahrzehnten erfolgreich für die Behandlung gastroenterologischer Erkrankungen verwendet. Die Probiotika gelten aufgrund der langjährigen Erfahrung als sicher. Seit ca. 20 Jahren werden zunehmend Studien ins Leben gerufen, welche sowohl die Wirkung der Produkte klinisch bestätigen als auch die bisher unbekannten Wirkmechanismen aufklären sollen. Das in Mutaflor enthaltene Bakterium E. coli Nissle 1917 wurde bereits erfolgversprechend in klinischen Studien zur Remi
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography